LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
Tweet
Share
E-mailGet Alerts LOGC Hot Sheet
Join SI Premium – FREE
LogicBio Therapeutics (NASDAQ: LOGC) reported Q2 EPS of ($0.14), $0.10 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $33.6 million.
For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Immucell Corp (ICCC) Reports Q2 EPS of $0.20
- Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
